Sustained virological response rates with direct‐acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support approval or to expa...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of Virus Eradication Ročník 5; číslo 3; s. 138 - 144
Hlavní autori:	Struble, Kimberly, Chan-Tack, Kirk, Qi, Karen, Valappil, Thamban, Connelly, Sarah, Mishra, Poonam, Price, Dionne, Murray, Jeffrey, Birnkrant, Debra
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Mediscript Ltd 18.09.2019 Elsevier
Predmet:	clinical trial Food and Drug Administration hepatitis C Original Research clinical trial hepatitis C Food and Drug Administration
ISSN:	2055-6640, 2055-6659
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!